Prelude Capital Management, LLC Puma Biotechnology, Inc. Transaction History
Prelude Capital Management, LLC
- $1.12 Billion
- Q3 2025
A detailed history of Prelude Capital Management, LLC transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 38,422 shares of PBYI stock, worth $190,188. This represents 0.02% of its overall portfolio holdings.
Number of Shares
38,422
Previous 33,422
14.96%
Holding current value
$190,188
Previous $114,000
72.81%
% of portfolio
0.02%
Previous 0.01%
Shares
10 transactions
Others Institutions Holding PBYI
# of Institutions
135Shares Held
35.2MCall Options Held
264KPut Options Held
0-
Acorn Capital Advisors, LLC New York, NY4.13MShares$20.4 Million11.14% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.69MShares$18.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.57MShares$17.7 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.15MShares$10.6 Million0.02% of portfolio
-
Acadian Asset Management LLC Boston, MA2.05MShares$10.2 Million0.02% of portfolio
About PUMA BIOTECHNOLOGY, INC.
- Ticker PBYI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,556,000
- Market Cap $226M
- Description
- Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...